AlphaMark Advisors’s Molina Healthcare MOH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
$1.09M Buy
3,744
+136
+4% +$42K 0.47% 49
2024
Q3
$1.24M Buy
3,608
+65
+2% +$21.4K 0.43% 44
2024
Q2
$1.05M Buy
3,543
+40
+1% +$13.6K 0.37% 47
2024
Q1
$1.44M Sell
3,503
-108
-3% -$41.8K 0.51% 37
2023
Q4
$1.3M Sell
3,611
-57
-2% -$20.1K 0.5% 38
2023
Q3
$1.2M Sell
3,668
-4
-0.1% -$1.26K 0.52% 39
2023
Q2
$1.11M Sell
3,672
-724
-16% -$208K 0.51% 44
2023
Q1
$1.18M Buy
4,396
+155
+4% +$44.5K 0.53% 44
2022
Q4
$1.4M Sell
4,241
-98
-2% -$33.3K 0.7% 38
2022
Q3
$1.43M Buy
4,339
+50
+1% +$16.1K 0.71% 34
2022
Q2
$1.2M Buy
4,289
+31
+0.7% +$9.37K 0.55% 45
2022
Q1
$1.42M Sell
4,258
-99
-2% -$30.5K 0.53% 49
2021
Q4
$1.39M Buy
4,357
+1
+0% +$297 0.48% 50
2021
Q3
$1.18M Buy
4,356
+66
+2% +$17.4K 0.43% 51
2021
Q2
$1.09M Buy
4,290
+81
+2% +$20.4K 0.4% 52
2021
Q1
$984K Buy
+4,209
New +$939K 0.38% 53

Other funds holding MOH

AlphaMark Advisors's MOH Position: Q4 2024 in Review

AlphaMark Advisors increased its Molina Healthcare (MOH) stake by 3.8% in Q4 2024, buying an estimated $42K and bringing the position to 3,744 shares worth $1.09M. The position accounts for 0.47% of the portfolio, ranked #49.

AlphaMark Advisors first reported a position in MOH in Q1 2021 and has held it in 16 quarters since. The position peaked at $1.44M in Q1 2024. 634 funds tracked by Wall St. Rank hold MOH as of Q4 2024.

  • AlphaMark Advisors held 3,744 shares of Molina Healthcare worth $1.09M as of Q4 2024.
  • AlphaMark Advisors bought 136 Molina Healthcare shares in Q4 2024, an estimated $42K.
  • Molina Healthcare made up 0.47% of AlphaMark Advisors's portfolio in Q4 2024, its #49 holding.
  • AlphaMark Advisors first reported a position in Molina Healthcare in Q1 2021 and has held it in 16 quarters since.
  • AlphaMark Advisors's Molina Healthcare position peaked at $1.44M in Q1 2024.
  • 634 funds tracked by Wall St. Rank held Molina Healthcare as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.